Recently, NMPA (National Medical Products Administration) approved the class-1 innovative drug Zongaitinib Tablets (Trade name: Shenghetu) conditionally via the priority review and approval pathway, developed by Boehringer Ingelheim International GmbH. Zongertinib as a monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have activating HER2 (ERBB2) mutations and who have received at least one-line prior systemic therapy. Its launch offers a new treatment option for patients.